Country
Italy
Angelini Pharma of Italy has agreed to spend up to $960 million to acquire a two-year old Swiss company with rights to an antiepileptic drug for the treatment of partial-onset seizures.
Full text available to subscribers only. Click here for information on subscribing to MedNous.